Nutritional Regulation of Cytochrome P450 (CYP3A4) Activity: A Clinical Evaluation of Clarithromycin Pharmacokinetics in Human Subjects Consuming High-Flavonoid Diets

Abstract

Background: Cytochrome P450 3A4 (CYP3A4) is a major enzyme involved in the metabolism of many clinically important drugs, including clarithromycin. Dietary flavonoids have been reported to modulate CYP3A4 activity, potentially influencing drug pharmacokinetics and therapeutic outcomes. Objective: To evaluate the effect of a high-flavonoid diet on clarithromycin pharmacokinetics and CYP3A4 activity in healthy human subjects. Methods: A randomized controlled crossover clinical study was conducted involving 24 healthy volunteers. Participants consumed a high-flavonoid diet (~500 mg/day) and a control low-flavonoid diet (<50 mg/day) in separate phases with a 14-day washout period. Clarithromycin (500 mg, single oral dose) was administered in each phase. Plasma drug concentrations were measured using validated HPLC-UV analysis, and CYP3A4 activity was assessed using the erythromycin breath test. Pharmacokinetic parameters including C_max, T_max, AUC_0–∞, and apparent clearance were calculated using non-compartmental analysis. Results: High-flavonoid dietary intake significantly increased CYP3A4 activity compared with the control diet phase (27.4 ± 3.1% vs 19.8 ± 2.5%, p < 0.01). Correspondingly, clarithromycin peak plasma concentration (C_max) and systemic exposure (AUC_0–∞) were significantly reduced under the high-flavonoid diet, while T_max remained unchanged, suggesting that dietary modulation primarily affected drug metabolism rather than absorption. Conclusion: High-flavonoid diets can modulate CYP3A4 activity in humans and significantly influence clarithromycin pharmacokinetics. These findings highlight the clinical importance of diet–drug interactions in pharmacotherapy involving CYP3A4 substrate medications. Nutritional counseling may be considered for patients receiving long-term therapy with such drugs.